Precision Dosing Through AI-Driven Personalized Therapy

Real-World Use Cases and Recommendations

Laura Behm, Pharm.D., BCPS December 2025

EXECUTIVE SUMMARY

For decades, pharmacotherapy has operated under a constrained paradigm: the "one-size-fits-all" model. Dosing regimens are typically derived from population averages established during pre-market clinical trials, which often exclude the very patients—the elderly, the multi-morbid, and the critically ill—who require the most complex care. Consequently, individual responses to medications vary widely due to genetic differences, dynamic organ function, and environmental factors, leading to a pervasive duality of suboptimal efficacy and avoidable toxicity.

Precision dosing aims to dismantle this legacy model by tailoring therapy to each patient's unique physiology. While the concept is not new, the capability to deliver it at scale is. Artificial Intelligence (AI) now offers the computational power to move beyond static nomograms to dynamic, adaptive learning systems. This white paper explores the transition to AI-driven precision dosing, highlighting real-world applications like CURATE.AI and deep learning pharmacokinetics. It outlines a strategic framework for implementation, arguing that the integration of AI does not replace the clinical pharmacist but rather elevates them to the role of a precision architect, capable of optimizing therapy with a level of granularity previously unattainable.

1. THE END OF THE "ONE-SIZE-FITS-ALL" ERA

Conventional dosing strategies often rely on linear regression equations or weight-based heuristics that fail to account for the non-linear dynamics of human physiology. In complex clinical scenarios—such as a liver transplant recipient navigating a narrow therapeutic index for tacrolimus, or a septic patient with rapidly fluctuating renal clearance requiring vancomycin—standard dosing nomograms are often little better than educated guesses. The result is a trial-anderror approach where therapeutic targets are missed,

resistance develops, or toxicity occurs before a steady state is achieved.

AI fundamentally alters this landscape by enabling Model-Informed Precision Dosing (MIPD). Unlike static calculators, AI algorithms can ingest multidimensional data streams—electronic health records (EHR), real-time vitals, laboratory trends, and genomic variants—to construct a "digital twin" of the patient's pharmacokinetic profile. This allows clinicians to predict drug exposure with high fidelity and adapt treatments proactively as the patient's condition evolves. The International Pharmaceutical Federation (FIP) has recognized this shift, noting in its recent policy statements that AI is essential for identifying patients at risk of non-adherence or adverse reactions and providing evidence-based, personalized recommendations.

2. EVIDENCE FROM THE FRONTIER: AI-GUIDED DOSING IN PRACTICE

The theoretical promise of precision dosing is now being validated by robust clinical evidence. One of the most prominent examples is CURATE.AI, an adaptive platform utilized in early trials for metastatic prostate cancer and transplant medicine.

CASE STUDY: CURATE.AI & Small Data

Unlike "Big Data" approaches that require millions of patients to train a model, CURATE.AI employs "Small Data"—using a small number of patient-specific dose-response data points to calibrate a model unique to that individual. In trials involving tacrolimus dosing for liver transplant patients, this approach demonstrated a quicker attainment of therapeutic drug concentrations, significantly reduced toxicity, and higher clinician confidence compared to standard protocols.

Similarly, machine learning is revolutionizing the management of anti-infectives. Deep learning models ap-

plied to vancomycin dosing have been shown to outperform traditional pharmacokinetic equations in predicting drug clearance and area under the curve (AUC). By learning from vast historical datasets of diverse patient populations, these models can accurately predict clearance even in patients with unstable renal function, enabling precise dosing regimens that minimize the risk of acute kidney injury (AKI) while ensuring bactericidal efficacy. Furthermore, the integration of pharmacogenomics into these AI systems allows for the prediction of drug-gene interactions—such as CYP2C9 and VKORC1 variants in warfarin therapy—to prevent bleeding events and subtherapeutic anticoagulation with a precision that human intuition cannot match.

3. THE AI-DRIVEN WORKFLOW: AUGMENTING CLINICAL JUDG-MENT

Implementing precision dosing requires a fundamental redesign of the clinical workflow. The process begins with the automated collection of patient-specific data, aggregating demographics, creatinine clearance trends, liver function tests, and available pharmacogenomic markers from the EHR. AI algorithms then process this data to build an individualized dose-response model. Crucially, these are adaptive algorithms; they update continuously as new drug levels and clinical outcomes are recorded, refining their predictions over the course of therapy.

CRITICAL: The Human-in-the-Loop

The generation of a recommendation is not the endpoint. The critical safety mechanism in this workflow is pharmacist oversight. Pharmacists must review AI-derived recommendations, verifying their appropriateness based on clinical context that the AI may miss—such as a patient's swallowing difficulty or specific goals of care. This "human-in-the-loop" supervision is essential to prevent harm and maintain professional accountability.

4. NAVIGATING BARRIERS TO ADOP-TION

Despite the clear benefits, the path to widespread adoption is fraught with challenges. The most immediate hurdle is technical robustness. AI models are voracious consumers of data, and they require high-quality, standardized inputs to function correctly. Inconsistent data entry, missing values, and lack of interoperability between EHRs and laboratory systems can degrade model performance. Furthermore, busy

clinicians may perceive AI tools as burdensome if they are not seamlessly integrated into existing workflows. User interfaces must be intuitive, minimizing clicks and providing clear, explainable rationales for every dosing recommendation.

Regulatory and ethical considerations also loom large. Under the impending EU AI Act, AI-driven dosing tools will likely be classified as "High Risk," necessitating rigorous testing, transparency, and human oversight. In the United States, these tools generally fall under the Software as a Medical Device (SaMD) framework, subject to FDA oversight. Clinicians and health systems must navigate these evolving regulations while also addressing the "black box" problem. Adoption depends on building trust; clinicians need education on AI methodologies to understand not just what the model recommends, but why, ensuring they remain the masters of the tool rather than its servants.

5. RECOMMENDATIONS FOR CLINI-CAL LEADERS

To successfully operationalize AI-driven precision dosing, pharmacy leaders should adopt a phased, strategic approach:

Prioritize High-Impact Medications: Begin implementation with drugs that have narrow therapeutic indices and high variability, such as tacrolimus, vancomycin, aminoglycosides, and warfarin. These agents offer the clearest return on investment in terms of safety and cost avoidance.

Launch Pilot Programs: Conduct prospective pilot studies comparing AI-guided dosing to standard of care. Measure tangible outcomes such as time to therapeutic range, reduction in adverse events, and length of stay to build a business case for broader adoption.

Establish Interdisciplinary Governance: Form collaborative teams comprising pharmacists, physicians, data scientists, and IT specialists. This diverse expertise is required to design, validate, and monitor models effectively.

Demand Transparency: When selecting vendors or building internal tools, prioritize interpretable models. Pharmacists must be able to interrogate the rationale behind a dose recommendation to explain it to prescribers and patients.

Institutionalize Algorithmovigilance: Implement continuous monitoring programs to detect "model drift" or bias. Just as we monitor drugs for side effects, we must monitor algorithms to ensure they remain accurate as patient populations and clinical guidelines evolve.

6. CONCLUSION

Precision dosing powered by AI represents a new frontier where computational power and pharmacist expertise converge. It offers the opportunity to maximize therapeutic benefit and minimize harm on a scale previously unattainable. However, technology alone is not the solution. The successful integration of these tools relies on the clinical judgment of the pharmacist. By embracing AI as a sophisticated instrument of care—incorporating patient-specific data, learning from real-world outcomes, and maintaining rigorous human oversight—pharmacists can lead the transition toward a healthcare system that treats the individual, not the average.

REFERENCES

- Artificial intelligence guided dosing decisions: a qualitative study on health care provider perspectives. PMC. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC12496069/.
- FIP Statement of Policy on Artificial Intelligence in Pharmacy. International Pharmaceutical Federation (FIP). Available at: https://www.fip.org/file/6354.
- Pharmacists Step Up To Monitor AI Algorithms. Healthcare Communications Network. Available at: https://hcn.health/hcntrends-story/pharmacists-step-up-to-monitor-aialgorithms/.
- Balancing Innovation and Control: The European Union AI Act in an Era of Global Uncertainty. PMC. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC12574960/.